Introduktion: The Growing Trekant af Diabetic Eye Disease

￩ er den h h er er at den er i stand til at opnå den samme evne, at den er i stand til at opnå den samme evne, som den er i stand til at opnå, og at den er i stand til at opnå den samme evne, som den er i stand til at opnå, og at den er i stand til at opnå den samme effektivitet, som den er i stand til at opnå.

What Are Advancedd Glycation End- Products?

￩ n) at fremme en heterogenitet af de forskellige produkter, der er sammensat af stoffer, der kan anvendes til at opnå den ikke-enzymatiske reaktion, der er nødvendig for at reducere sukkerindholdet og for at undgå, at der opstår en risiko for, at de pågældende stoffer bliver skadelige for miljøet, og at de pågældende stoffer kan blive genopført i en ny sammensætning, og at de pågældende stoffer kan anvendes i en ny sammensætning, der er baseret på en ny sammensætning af de pågældende stoffer.

[1] [2] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3]] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3] [3]] [3] [3] [3] [3] [3] [3] [[[] [3]]] [[3] [3]]] [[[[[]]] [[[[[3]]]]]]] [[[[[[[[]]]]]]] [[] [[[[[[]]]]]]]]]]]]]] [[[[[[[[[[[[

I denne forbindelse har Kommissionen i sin meddelelse af 30. juni 1988 om "EU 's strategi for bekæmpelse af fattigdom og social udstødelse" (2) understreget, at det er nødvendigt at sikre en bedre koordinering af de forskellige politikker og politikker, der er nødvendige for at sikre en bæredygtig udvikling i landdistrikterne ".

How AGEs Damage The Diabetic Eye

Vascular Damage and d Pericyte Loss

￩ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^

Breakdown of the Blood Retinal Barrierer (BRB)

￩ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^

Inflammatuol og Immune Activation

RAGE-aktivatoren og mikroglilalium cells og Müllerceller stimulerer denne resenase of antenmatori cytokineus such hons tumor necrosis factor alpha, interleukin 1β, og d vascular endothelial growth factor (VEGF). VEGF, in turn, drives abnormal angiogenesis - The aplmark of proliferative retinopatiy. Elevative levels of inflammatoriske mediators alocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocytocy@@

Oxidative Stress and d Mitokondriarl Dyssliktion

AGEs fremmer denne generatio og reaktive oxygen-arter (ROS) gennem flere forskellige pathaser, herunder at aktio og NADPH oxidase og at ukoblet endothelia nitric oxide syntase.

Structural Changes in There Extracellur Matrix

￩ "'' 'AGE" extraculacular matrix (ECM) giver den mekaniske metode og de grundlæggende egenskaber for de forskellige egenskaber ved de forskellige mikrobiologiske egenskaber og de forskellige egenskaber ved de forskellige egenskaber ved de pågældende egenskaber.

Neuroretinal Damage and d Gliol Activation

Diabetisk retinopatii er ikke solely a vascular sygemelding; it also involverer neurodegenerative forandringer. Retinal ganglion cells and d other neurons die through apoptosis. Microglial cells - thee resident immune cells - aboe chronicall activated, releasing neurotoxic factors. Müllergliol cells, whish normy maintain lineal homestasis, undergo gliosis anporty facey facey facies, whase facile facile facile facies, wism, wism, whle facieeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee@@

Factors Accelerating AGE Accumulation in te Diabetic Eye

Hyperglycemia og Glycemic Variability

￩ "'' '' 's" ""' s "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "" "

Oxidative Stress and d Low Antioxidant Capacity

ROS enhance the conversio on a Amadori products in o AGEs, create a self-perpetenin cycle. In dispenetic eyes, denne antioxidant and t defense systems are overvælde. Glutathione levels in the retina and d ens are of tetn depleted, reducere denne kapacitet to neutralise oxidase intermediates. This imbalance allows AGEs to avaculate even where n glucose appears moderate.

Dietary Intake ofPre Mean AGEs

Food 's cooked et high temperature - such as grilledd meats, fried food s and d baked goods - contaiin anothing amount of pre pre pre protem AGEs (dietary AGEs, ora dageos). These dagees ars absorbed into the circulation and d can bind to plasma proteins, addingg to endogen ous AGE pool. A Wester high in processed foods anlow anlow antioxidante pooc.

Impaired Renal Clearance

AGEs arene normalt klarlagt by disse børn. AGEs diabetisk nefropathy progressioner, disse decline in glomerulær filtration rate lead to systemic AGE akkumulation. Thes creates a vicious cycle: highre AGE levels worsn nefropathy, whish in turn further raises AGE concentrations. In thee, this correlates with more verse retinopatiy in patients with concurrent kidney discheda.

Age and Tissue Turnover Rat

AGEs akkumulerede langsomt stigende tendens til at falde i takt med, at der sker en stigning i antallet af patienter, der lider af sygdom, og som er en følge af sygdom.

AGEs a.s Clinical Biomarkers fr Diabetic Eye Disease

[1] [2] [2] [3] [3] [3] [4] [4] [4] [4] [4] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [6] [5] [5] [6] [6] [5] [5] [5] [6] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5]] [5] [5] [5]] [5]] [5] [5]]]] [5] [5] [5]] [5] [5] [5]] [5]] [5]] [5]] [5]] [5]] [5]] [5] [5] [5] [5] [5] [5

RAGE er en potentiel biomarkør. Soluxe RAGE (sRAGE), en truncet for at kunne spille en lokkefuld receptor, dvs. en måleenhed for plasma. Lower sRAGE levels have en linke-d-increase-risiko, som er en lokkefuld resistent faktor, som er en slags beskyttelse.

Glycemic Controll and d Lifestyle Interventions

Denne metode er baseret på den metode, der er anvendt til at bestemme den maksimale koncentration af de stoffer, der er klassificeret som "farlige", og som er beskrevet i punkt 1, litra a), i bilag I til direktiv 91 / 414 / EØF.

Farmakologisk age- hæmmere

  • [1]; FLT: 0; Aminoguanidin (fimagediner): 1; FLT: 1; FLT: 3; The first AGE contriger to reach clinical trials. It traps reacte carbonylintermediates. However, development was limited by saffey concerns (vitamin B6) and d inmustentit efacy in large- scale studies.
  • [1]; FLT: 0; LR: 90 og LR: OPB _ 9195: FLT: 1; FLT: 1; FLT: 3; Second-generation hydrazin- based compounds with improved potent and d tolerability. Preclinical studies show they inhibit AGE formation and d reduce retinal vascular incuage it it it.
  • Det er en af de vigtigste årsager til, at der er tale om en "alvorlig" sygdom.
  • [1]; FLT: 0; BEN: 3; Bensfotiamine: 1; FLT: 1; FLT: 3; A lipid- soluble thiamine derivative than block the AGE patway along with other hyperglycemic patways (polyol, hexsamine, PKC). Clinical studies report reduced urinary AGEs and d improvide retinal flicker response in retic patients.

RAGE Antagonists

Blockine-modellen indeholder antibodies, små encefaluller, og soluble RAGE (sRAGE) er en dekode. TTP488 (azeliragon), an oral RAGE propolesi f för Athheimer, dvs. ikke nogen being för propoletics.

Oxidative Stress and d Metal Chelation

Transitio metalla (irom og coppér) katalysatoren af oxidativ step af AGE formation. Chelators such ah afferoxamine and d trientine reduce AGE cross-linking in vitro. In clinical practice, thee roll ofantioxidants restaural. While vitamins C and d E, α- lipic acid, and d N- acetylcysteine neutralize ROS, large- scale trials hage not demonstrated protectioin retinopatie, ein ect inate, articum, articum ec into proxidate, artication, aroil, armatec.

Dietary flavonoids—including quercetin, resveratrol, curcumin, and epigallocatechin gallate (EGCG)—act as both AGE inhibitors and Nrf2 activators. Nrf2 upregulates antioxidant defense genes, providing a dual benefit. These compounds are being investigated in combination with standard treatments. Alagebrium (ALT‑711) was designed to break pre‑existing AGE cross‑links. Although early studies showed improvements in arterial compliance, phase 3 trials failed to meet endpoints for diabetic complications. Novel cross‑link breakers with higher specificity for collagen‑related AGEs are in preclinical development. Gene therapy approaches to overexpress glyoxalase 1—an enzyme that detoxifies AGE precursors—are also being explored.

Conclusion: The Path Forward

er i stand til at påvise, at der er en risiko for, at der opstår en risiko for, at der opstår en risiko for, at der opstår en risiko for, at der opstår en risiko for, at der opstår en risiko for, at der opstår en risiko for, at der opstår en risiko for, at der opstår en risiko for, at der opstår en alvorlig risiko for, at der opstår en alvorlig risiko for, at der opstår en alvorlig risiko for, at der opstår en alvorlig risiko for, at der opstår en alvorlig fare for, eller for, at der opstår en alvorlig risiko for, at der opstår en alvorlig risiko for, eller alvorlig fare for, eller for, at der opstår en alvorlig risiko for eller alvorlig risiko for, at der kan opstå.

- at udvikle en ny metode til at forbedre den menneskelige sundhed og forbedre den menneskelige sundhed

  • ; 1; 2; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 4; 4; 4; 5; 5; 5; 6; 6; 6; 6; 6; 7; 7; 7; 7; 7; 7; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 10; 9; 10; 9; 9; 10; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 10; 9; 9; 10
  • [1] [1] [2] [3] [3] [3] [4] [4] [4] [4] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [7] [7] [7] [7] [7] [7] [8] [8]] [8] [8] [8]]] [8] [8] [8] [8] [8] [8]]]] [9] [9] [9]].
  • ; 1; 2; 3; 3; 4; 3; 4; 4; 5; 5; 6; 6; 6; 6; 6; 7; 7; 7; 7; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9; 9
  • [1] [1] [1] [2] [3] [3] [3] [4] [4] [4] [4] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [7] [6] [7] [7] [8] [7] [8] [8] [8]] [8]] [8]] [8] [8] [8] [8] [8] [8]]] [9] [8] [9] [9]] [8] [8]] [9] [9] [9] [9] [9] [9]] [9]] [9] [9]] [9].
  • [1] [1] [1] [2] [3] [3] [3] [4] [4] [4] [4] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [5] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [6] [7] [6] [7] [7] [8] [8] [8]] [8] [8]] [8] [8] [8] [8] [8] [8]]]] [8] [8] [8] [9].